These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38785484)

  • 1. Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation.
    Potkrajcic V; Gani C; Fischer SG; Boeke S; Niyazi M; Thorwarth D; Voigt O; Schneider M; Mönnich D; Kübler S; Boldt J; Hoffmann E; Paulsen F; Mueller AC; Wegener D
    Curr Oncol; 2024 May; 31(5):2679-2688. PubMed ID: 38785484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First Experience and Prospective Evaluation on Feasibility and Acute Toxicity of Online Adaptive Radiotherapy of the Prostate Bed as Salvage Treatment in Patients with Biochemically Recurrent Prostate Cancer on a 1.5T MR-Linac.
    Wegener D; Thome A; Paulsen F; Gani C; Boldt J; Butzer S; Thorwarth D; Moennich D; Nachbar M; Müller AC; Zips D; Boeke S
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36012885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
    Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
    BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
    Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
    Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
    Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
    Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-Linac: Estimated delivered dose and early toxicity results.
    Gao L; Wei R; Qin S; Tian Y; Xia W; Song Y; Wang S; Fang H; Tang Y; Jing H; Liu Y; Tang Y; Qi S; Chen B; Li Y; Xing N; Lu N
    Chronic Dis Transl Med; 2024 Mar; 10(1):51-61. PubMed ID: 38450305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy.
    Westerhoff JM; Daamen LA; Christodouleas JP; Blezer ELA; Choudhury A; Westley RL; Erickson BA; Fuller CD; Hafeez S; van der Heide UA; Intven MPW; Kirby AM; Lalondrelle S; Minsky BD; Mook S; Nowee ME; Marijnen CAM; Orrling KM; Sahgal A; Schultz CJ; Faivre-Finn C; Tersteeg RJHA; Tree AC; Tseng CL; Schytte T; Silk DM; Eggert D; Luzzara M; van der Voort van Zyp JRN; Verkooijen HM; Hall WA
    JAMA Netw Open; 2024 May; 7(5):e2410819. PubMed ID: 38691356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy.
    Sandoval ML; Rishi A; Latifi K; Grass GD; Torres-Roca J; Rosenberg SA; Yamoah K; Johnstone PAS
    Cancer Control; 2024; 31():10732748241270595. PubMed ID: 39206515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
    Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
    Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
    Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
    Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
    Marciscano AE; Wolfe S; Zhou XK; Barbieri CE; Formenti SC; Hu JC; Molina AM; Nanus DM; Nauseef JT; Scherr DS; Sternberg CN; Tagawa ST; Nagar H
    BMC Cancer; 2023 Aug; 23(1):781. PubMed ID: 37608258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
    Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial.
    Ristau J; Hörner-Rieber J; Buchele C; Klüter S; Jäkel C; Baumann L; Andratschke N; Garcia Schüler H; Guckenberger M; Li M; Niyazi M; Belka C; Herfarth K; Debus J; Koerber SA
    Radiat Oncol; 2022 Apr; 17(1):75. PubMed ID: 35428327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, toxicity, and quality-of-life outcomes of ultrahypofractionated radiotherapy in patients with localized prostate cancer: A single-arm phase 2 trial from Asia.
    Tan JSH; Teh JYH; Tan LLY; Tan SXF; Li YQ; Tan TWK; Wang MLC; Kanesvaran R; Ong EHW; Tay KJ; Lee LS; Tuan JKL; Tan DYH; Chua MLK
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e346-e355. PubMed ID: 34908240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
    Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer.
    Jereczek-Fossa BA; Maucieri A; Marvaso G; Gandini S; Fodor C; Zerini D; Riva G; Alessandro O; Surgo A; Volpe S; Fanetti G; Arculeo S; Zerella MA; Parisi S; Maisonneuve P; Vavassori A; Cattani F; Cambria R; Garibaldi C; Starzyńska A; Musi G; De Cobelli O; Ferro M; Nolè F; Ciardo D; Orecchia R
    Med Oncol; 2018 Nov; 36(1):9. PubMed ID: 30483899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
    Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.